Sugi Predict

Sugi Predict / Targets / PLA2G12A

PLA2G12A

Group XIIA secretory phospholipase A2 · Q9BZM1 · PLA2G12A on Sugi Atlas →

1,510 patent compounds predicted against PLA2G12A, 1,049 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3335072 SCHEMBL3335072 0.58 3/20
SCHEMBL3341807 SCHEMBL3341807 0.56 3/20
SCHEMBL3337877 SCHEMBL3337877 0.51 3/20
SCHEMBL3338398 SCHEMBL3338398 0.51 2/20
SCHEMBL3340881 SCHEMBL3340881 0.40 2/20
Varespladib Varespladib (SCHEMBL26726) 1.00 1/20
SCHEMBL7682372 SCHEMBL7682372 0.87 1/20
SCHEMBL818585 SCHEMBL818585 0.85 1/20
SCHEMBL5150404 SCHEMBL5150404 0.84 1/20
Varespladib Methyl Varespladib Methyl (SCHEMBL25678) 0.83 1/20
Varespladib Varespladib (SCHEMBL1232548) 0.83 1/20
SCHEMBL5710595 SCHEMBL5710595 0.82 1/20
SCHEMBL5710700 SCHEMBL5710700 0.82 1/20
SCHEMBL5710708 SCHEMBL5710708 0.82 1/20
SCHEMBL6812616 SCHEMBL6812616 0.82 1/20
SCHEMBL5710565 SCHEMBL5710565 0.80 1/20
SCHEMBL5710591 SCHEMBL5710591 0.80 1/20
SCHEMBL7171270 SCHEMBL7171270 0.80 1/20
SCHEMBL5710584 SCHEMBL5710584 0.79 1/20
SCHEMBL7962736 SCHEMBL7962736 0.79 1/20

Clinical trials — most relevant to PLA2G12A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study PHASE4COMPLETED
Comparison of Simvastatin Versus Simvastatin/Ezetimibe on Small Dense Low -Density Lipoprotein (LDL) PHASE4COMPLETED
A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis PHASE3COMPLETED
Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes PHASE3UNKNOWN
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy PHASE3COMPLETED
European Celecoxib Trial in Primary Breast Cancer PHASE3COMPLETED
Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM PHASE3COMPLETED
Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study PHASE2/PHASE3RECRUITING
Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) PHASE1/PHASE2COMPLETED
Assessment of Coronary Plaque Composition PHASE1COMPLETED
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy nanCOMPLETED
Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes nanCOMPLETED
Effect of B-cell Depleting Therapies on PLA2R-specific B Cells in Patients With Membranous Nephropathy nanCOMPLETED
Role of PLA2G1B During HIV Infection nanUNKNOWN
Plasma Free Fatty Acids Profile As A Diagnostic Tool For Acute Ischemic Stroke nanCOMPLETED
Mucomyst for Hepatitis C nanSUSPENDED
Clinical Trial of Anti-PLA2R-IgG Detection Kit (Time-resolved Fluorescence Immunoassay) nanCOMPLETED
EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) nanUNKNOWN
An Outcome Analysis of Primary Membranous Nephropathy nanRECRUITING
Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies nanUNKNOWN
Molecular Markers of Human Sperm Function nanWITHDRAWN
Positron Emission Tomography (PET) to Study Brain Signaling nanCOMPLETED
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy nanCOMPLETED
Oxidative Stress, Anxiety and Depression in Breast Cancer Patients: Impact of Music Therapy nanCOMPLETED
Investigation of Lipoxin A4, Annexin A1 and Interleukin-1 Beta Levels in Individuals With Periodontitis. nanCOMPLETED
Markers in Acute Pancreatitis-1 nanCOMPLETED
Lp-PLA2 and Coronary Atherosclerosis in Humans nanCOMPLETED
LDL-Apheresis for FSGS CardioRenal Outcomes nanCOMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations nanCOMPLETED
Omics of Rituximab-resistance nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLA2G12A binder may also engage these)

ProteinNameSimilarity
Q9EPR2 — 1.000 Q9EPR2 →
P0DXZ6 — 0.989 P0DXZ6 →
Q4VRI5 — 0.985 Q4VRI5 →
G9I930 — 0.985 G9I930 →
P00630 — 0.983 P00630 →
Q9QZT4 — 0.983 Q9QZT4 →
Q8GZB4 — 0.982 Q8GZB4 →
A0A5C1ZXT8 — 0.982 A0A5C1ZXT8 →
Q9W7J4 — 0.982 Q9W7J4 →
Q8BH35 — 0.982 Q8BH35 →
I7GQA7 — 0.982 I7GQA7 →
Q9R097 — 0.982 Q9R097 →
A0A1L4BJ46 — 0.982 A0A1L4BJ46 →
P00615 — 0.981 P00615 →
P30811 — 0.981 P30811 →
P20146 — 0.981 P20146 →
P00611 — 0.980 P00611 →
P55314 — 0.980 P55314 →
Q45Z27 — 0.980 Q45Z27 →
Q92086 — 0.980 Q92086 →
P63057 — 0.980 P63057 →
P63056 — 0.980 P63056 →
Q8GV50 — 0.980 Q8GV50 →
P80966 — 0.980 P80966 →
A0A5C2A2T2 — 0.980 A0A5C2A2T2 →
Q92085 — 0.979 Q92085 →
P58239 — 0.979 P58239 →
P00619 — 0.979 P00619 →
Q9PUH2 — 0.979 Q9PUH2 →
E9Q6D8 — 0.979 E9Q6D8 →